http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020300043-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_374bd30b140c412aedda14571cbbc4a7
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2826
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
filingDate 2020-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2594704a2952dd36e5a513556f0f5e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e25aca6d5b04c1cd1372509f91d27a60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dde1df7a79b5c4ceabbfab4a151136ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b96d6e9b141600f94570601cb95adbc4
publicationDate 2022-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2020300043-A1
titleOfInvention Pharmaceutical composition of darolutamide
abstract The present invention relates to a pharmaceutical composition for oral administration, particularly in the form of a tablet, comprising darolutamide or a pharmaceutically acceptable salt thereof as an active ingredient. Darolutamide is a potent androgen receptor (AR) modulator useful in the treatment of cancer, particularly AR dependent cancer such as prostate cancer, and other diseases where AR antagonism is desired.
priorityDate 2019-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448380735
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433322677
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449454525
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67171867
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448897384
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23665634
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104805
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526466
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9883259
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453754419
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413976492
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452788844
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62223
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62698
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3423265
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154496863
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID84571
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID440995
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449159271
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453837589
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24441
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474324
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177

Total number of triples: 55.